Squalamine and its Derivatives as Potential Antitubercular Compounds Correspondance

To the Editor,
Squalamine is an aminosterol isolated from the dogfish shark Squalas acanthias and identified for its antimicrobial activity. 1 It also inhibits the growth of blood vessels within solid tumors and has been widely investigated as an antitumor agent, and has been included in clinical trials. 2 Squalamine has been shown to possess improved antitumor activity when co-administered with carboplatin or cisplatin. 3 Recently, its potential therapeutic spectrum has been widened by the discovery of broad-spectrum systemic antiviral activity. 4 We believe squalamine itself or squalamine derivatives are a potential class of targeted antitubercular agents. The hypothesis that these derivatives might work in this way is based on two characteristics of Mycobacterium tuberculosis (MTB): the waxy, hydrophobic barrier provided by mycolic acids on the mycobacterial surface, and the affinity of mycobacteria for cholesterol. There are both steroidal and amphiphilic compounds have antimycobacterial activity and may be able to permeate the fatty acid layers of this structure because of their non-polar carbon based skeleton. 5 Furthermore, lipophilic fatty acid derivatives have been shown to be active against several strains of mycobacteria, including ones that were multidrug resistant (MDR). 6 One critical protein that is contained by MTB during macrophage invasion is the tryptophane aspartate-containing coat protein (TACO). 7 Mycobacteria actively recruit and retain TACO to prevent fusion with lysosomes. After phagocytosis, macrophages are normally converted to lysosomes, which degrade consumed material, but mycobacteria retain TACO at the phagosome stage, which prevent conversion to lysosomes. 8 This absence of lysosomes helps ensure the survival of MTB within the macrophage. Importantly from a drug targeting standpoint, TACO associates with the phagosome in a cholesterol dependent manner. Cholesterol inhibition reduces macrophage uptake of M. bovis by 85-90% and MTB by 85%, and mycobacteria display an intrinsic high binding capacity for cholesterol. 7 The affinity of mycobacteria for cholesterol could be exploited by designing drugs that have structural similarities to cholesterol. Previously, we have synthesized neomycincholesterol hybrids in an attempt to engineer this uptake mechanism.
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The mechanism for the antimicrobial activity of squalamine has been widely studied and initially it was believed to act as a proton ionophore. in antimicrobial activity suggest that these agents are acting upon specific sites in each organism that differs for each organism. Another study showed that squalamine is not a proton ionophore 10 and recent work indicates its antibacterial action results from membrane depolarization. 11 This information leads us to believe that the 24-sulfate may not be necessary for antimicrobial activity. 12 Thus, we initially targeted compounds 1 and 2 as our model squalamine analogs to test their physicochemical properties ( Figure 1 ). However, initial attempts to dissolve or formulate this compound for antimycobacterial studies proved difficult. In the electrospray mass spectra of this and related compounds, dimers and trimers were often observed. The amphiphilic nature of this compound may require coadministration of a cyclodextrin or some other solubilizing agent to disrupt aggregation. The tendancy toward self-aggregation by 1 may be diminished when an axial hydroxy group is added at C-7 (e.g.-2) as is present in squalamine itself. This axial alcohol is also present in the natural surfactant cholic acid (albeit with a differing configuration at the AB bridgehead C-5). In fact, a patent on the 3-epimer of this compound and close derivatives of squalamine has recently been filed for use as antidiabetic agents indicative of improved physicochemical properties for 2 relative to 1. 14 Although we have been unable to obtain antimycobacterial data on these compounds, due to the desperate need for new TB drugs, 15 we would encourage those who have access to the natural product to have it tested against MDR-TB as we are not aware of any such study.
